-
1.发明公开
公开(公告)号：EP3868740A1
公开(公告)日：2021-08-25
申请号：EP19872471.8
申请日：2019-10-17
发明人： TAKEOKA, Shinji , NAKAHARA, Keiko , NISHIURA, Mamoru , OTSUBO, Shinya , KURUMATANI, Hajimu , ARAKANE, Toru
IPC分类号： C07C233/05 , A61K31/225 , A61P7/04 , C07K5/00 , C07K7/00
摘要： An object of the present invention is to provide a carboxylic acid-type lipid that can accelerate adhesion or aggregation of platelets even if the carboxylic acid-type lipid does not carry a protein involved in adhesion or aggregation of platelets, such as GPIb and H12, or a peptide corresponding to an active site of the protein; a lipid particle and a lipid membrane each comprising the carboxylic acid-type lipid; and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each comprising the carboxylic acid-type lipid, the lipid particle or the lipid membrane, and, in order to achieve the object, the present invention provides a carboxylic acid-type lipid selected from carboxylic acid-type lipids represented by formulas (I) to (VI), a lipid particle comprising the carboxylic acid-type lipid, a lipid membrane comprising the carboxylic acid-type lipid, and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each comprising the carboxylic acid-type lipid, the lipid particle or the lipid membrane.
-
公开(公告)号：EP3868413A1
公开(公告)日：2021-08-25
申请号：EP19873651.4
申请日：2019-10-17
发明人： TAKEOKA, Shinji , NAKAHARA, Keiko , NISHIURA, Mamoru , OTSUBO, Shinya , KURUMATANI, Hajimu , ARAKANE, Toru , TAKEDA, Masanobu , NAKAHARA, Makoto , OYAMA, Kumi
IPC分类号： A61L15/20 , A61K9/127 , A61K9/70 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61L15/26 , A61L15/28 , A61L15/42 , A61L15/64
摘要： An object of the present invention is to provide a hemostatic material comprising a lipid that can accelerate adhesion or aggregation of platelets even if the lipid does not carry a protein or a peptide involved in adhesion or aggregation of platelets, such as GPIb and H12, and, in order to achieve the object, the present invention provides a hemostatic material (10) comprising a water-insoluble base (1) and a lipid supported on a surface of the base (2), wherein the lipid comprises one or two or more anionic lipids.
-
公开(公告)号：EP1913946B1
公开(公告)日：2014-03-05
申请号：EP06767982.9
申请日：2006-07-07
IPC分类号： A61K31/5578 , A61K31/5585 , A61P13/12 , C07D307/93
CPC分类号： A61K31/343 , A61K31/5578 , A61K31/5585 , C07D307/93
摘要： A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I 2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.
-
4.发明公开PLASMINOGEN ACTIVATOR INHIBITOR 1 PRODUCTION REGULATORY AGENTS 审中-公开MITTEL ZUR REGULATION DER PRODUKTION DES PLASMINOGEN-AKTIVATOR-INHIBITORS 1
公开(公告)号：EP1022030A1
公开(公告)日：2000-07-26
申请号：EP99937016.6
申请日：1999-08-10
IPC分类号： A61K45/00 , A61K31/557
CPC分类号： A61K31/557 , A61K31/00 , A61K31/343
摘要： Agents regulating the production of plasminogen activator inhibitor 1 which contain as the active ingredient intracellular cyclic AMP-augmenting substances.
摘要翻译： 调节纤维蛋白溶酶原激活物抑制剂1的生产的试剂，其含有作为活性成分的细胞内环AMP增强物质。
-
公开(公告)号：EP2305653A1
公开(公告)日：2011-04-06
申请号：EP09800423.7
申请日：2009-07-23
IPC分类号： C07D241/20 , A61K31/4965 , A61K31/497 , A61P7/06 , A61P13/12 , A61P43/00 , C07D403/12
CPC分类号： C07D241/20 , A61K31/4965
摘要： The present invention aims to provide a therapeutic agent for chronic renal failure, comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof. That is, the present invention provides provision of a drug comprising as an effective ingredient a compound represented by General Formula (1) or a pharmaceutically acceptable salt thereof, which drug is useful not only for amelioration of renal function, but also for amelioration of anemia, activation of SOD and excretion of uremic substances.
-
公开(公告)号：EP1106176B1
公开(公告)日：2008-06-18
申请号：EP00925584.5
申请日：2000-05-10
IPC分类号： A61K31/343 , A61K31/5585 , A61P13/12
CPC分类号： A61K31/5585 , A61K31/343
摘要： Remedies for renal failure containing a 4,8-inter-m-phenylene prostaglandin I2 derivative as the active ingredient; and a method for treating renal failure by using the same.
-
7.发明公开THERAPEUTIC AGENT AND TREATMENT METHOD FOR AMELIORATING UREMIA 有权治疗麻醉品麻醉品牌伦敦伦敦维多利亚ZUR LINDERUNG VONURÄMIE
公开(公告)号：EP1913946A1
公开(公告)日：2008-04-23
申请号：EP06767982.9
申请日：2006-07-07
IPC分类号： A61K31/5578 , A61K31/5585 , A61P13/12 , C07D307/93
CPC分类号： A61K31/343 , A61K31/5578 , A61K31/5585 , C07D307/93
摘要： A therapeutic agent and a treatment method for uremia of human and animals, which therapeutic agent can be easily taken, has lower side effects, and which is not expensive in view of medical economics, are disclosed. The therapeutic agent for uremia in patients suffering from chronic renal failure comprises as an effective ingredient a prostaglandin I 2 derivative having a specific structure, such as beraprost sodium. The therapeutic agent for uremia ameliorates the uremia concurred in patients with chronic renal failure without accompanying side effects, and restoration of decreased appetite, improvements in activities, increase in body weight and the like are achieved. The therapeutic effect of uremia is clear alleviation or disappearance of symptoms of uremia grasped as clinical symptoms, observed in the state of renal failure, especially even in spite of the state wherein the decrease in renal function is progressed.
摘要翻译： 公开了治疗剂和治疗剂可以容易地服用的治疗剂和治疗方法，其副作用较小，并且在医学经济学方面不贵。 用于患有慢性肾功能衰竭的患者的尿毒症治疗剂包括作为有效成分的具有特定结构的前列腺素I 2衍生物，例如贝前列素钠。 用于尿毒症的治疗剂可以改善慢性肾功能衰竭患者的尿毒症，而不伴随副作用，恢复食欲降低，活动改善，体重增加等。 尿毒症的治疗效果是在肾功能衰竭状态下观察到的作为临床症状的尿毒症症状明显缓解或消失，特别是即使肾功能下降进行的状态也是如此。
-
公开(公告)号：EP0925788A1
公开(公告)日：1999-06-30
申请号：EP98907187.3
申请日：1998-03-12
IPC分类号： A61K31/557
CPC分类号： A61K31/5585
摘要： The present invention provides a diabetic angiopathy improving agent comprising a prostaglandin I derivative such as beraprost as an active component, and a method of preventing diabetic angiopathy by using the improving agent. This medicine exhibits excellent effects as a diabetic angiopathy inhibiting agent in both oral administration and parenteral administration.
摘要翻译： 本发明提供一种糖尿病血管病改善剂，其包含贝前列素等前列腺素I衍生物作为有效成分，以及使用该改善剂来预防糖尿病血管病的方法。 该药在口服给药和肠胃外给药中均显示出优异的作为糖尿病血管病抑制剂的效果。
-
公开(公告)号：EP2305653B9
公开(公告)日：2015-06-24
申请号：EP09800423.7
申请日：2009-07-23
IPC分类号： C07D241/20 , A61K31/4965 , A61K31/497 , A61P7/06 , A61P13/12 , C07D403/12
CPC分类号： C07D241/20 , A61K31/4965
-
10.发明授权
公开(公告)号：EP1016408B1
公开(公告)日：2006-04-19
申请号：EP98943009.5
申请日：1998-09-16
发明人： KURUMATANI, Hajimu , SASAKI, Rie , KUMAGAI, Hiroki
IPC分类号： A61K31/557 , C07D307/93
CPC分类号： A61K31/5585 , C07D307/93
摘要： A C-C chemokine production inhibitor comprising a prostatnoic acid derivative as the active ingredient and a method for inhibiting the production of C-C chemokine by using the same. The inhibitor is useful for the treatment of circulatory system disorders, inflammations, allergic diseases, kidney diseases and the like.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.016 秒)
